文献速递衰弱、肌少症与跌倒老年综合评估

随机对照试验中衰弱测量与分析的范围综述

A scoping review of the measurement and analysis of frailty in randomised controlled trials.
PubMed 文献 · Age Ageing · 2024-01-01

该范围综述检索五个电子数据库,纳入415项在参与者中测量衰弱的随机对照试验,分析衰弱测量的目的与工具。衰弱用于定义目标人群、作为结局、效应修饰因子、描述性特征或预后标志物;共使用28种衰弱测量工具加29种试验特异性工具,衰弱表型模型和累积缺陷衰弱指数最常用。结论认为试验中衰弱测量高度可变。

要点

  • 415项RCT中衰弱用于定义目标人群166项、作为结局156项、效应修饰61项、描述性42项、预后标志物78项。
  • 共使用28种衰弱测量工具及29种试验特异性工具,衰弱表型模型最常用(164项试验)。
  • 累积缺陷衰弱指数用于102项试验,在评估治疗效应修饰的试验中最常见(21/61项)。

核心结论

  • 随机对照试验中衰弱测量高度可变,需理解各测量工具特性及其与临床实践中衰弱的关系。

研究设计与样本

  • 范围综述,检索五个电子数据库,纳入415项在试验参与者中测量衰弱的随机对照试验。

主要发现

  • 衰弱用于定义目标人群166项试验、作为结局156项、作为效应修饰因子61项、作为纯描述性特征42项、作为预后标志物78项。
  • 试验共使用28种衰弱测量工具,另加29种试验特异性测量工具。
  • 衰弱表型模型总体最常用(164项试验),用于定义目标人群90/166项、作为结局81/156项。
  • 累积缺陷衰弱指数用于102项试验,在评估治疗效应修饰的试验中最常见(21/61项)。

临床怎么用

  • 解读RCT衰弱相关结果时需关注其使用的衰弱测量工具及评估目的,避免跨试验直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is of increasing interest in trials, either as a target of intervention, as an outcome or as a potential treatment modifier. However, frailty measurement is often highly variable. This scoping review assessed how frailty is quantified in randomised controlled trials (RCTs), in what context and for what purposes. METHODS: We searched five electronic databases for RCTs in which frailty was measured among trial participants. We extracted data on intervention type, the frailty measure used and the purpose for which frailty was assessed. We then compared these data according to reasons for frailty assessment. RESULTS: We identified 415 RCTs assessing frailty across a range of interventions. Frailty was used to define the target population (166 trials), as an outcome (156 trials), as an effect modifier examining interaction of frailty on treatment effect (61 trials), as a purely descriptive characteristic (42 trials) or as a prognostic marker examining the impact of frailty on future health outcome (78 trials). The trials used 28 different measures of frailty (plus 29 additional trial-specific measures). The frailty phenotype model was the most common overall (164 trials), for defining the target population (90/166 trials) and as an outcome (81/156 trials). The cumulative deficit model frailty index was also frequently used (102 trials) and was most common among trials assessing treatment effect modification (21/61 trials). CONCLUSION: Frailty measurement in RCTs is highly variable. Understanding the properties of respective frailty measures and how these relate to frailty as encountered in clinical practice is a priority to ensure that trial findings can inform healthcare delivery for people living with frailty.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Sun Y, Witham MD, Clegg A, et al. A scoping review of the measurement and analysis of frailty in randomised controlled trials. Age Ageing. 2024. PMID: 39572393. doi:10.1093/ageing/afae258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。